0.8226
price down icon3.22%   -0.0274
after-market After Hours: .80 -0.0226 -2.75%
loading
Metavia Inc stock is traded at $0.8226, with a volume of 122.40K. It is down -3.22% in the last 24 hours and down -48.07% over the past month. MetaVia Inc Formerly NeuroBo Pharmaceuticals Inc is a clinical-stage biotechnology company focused predominantly on developing and commercializing novel pharmaceuticals to treat cardiometabolic diseases. The company has two primary programs focused on the treatment of metabolic dysfunction-associated steatohepatitis (MASH), and obesity. Its product pipeline includes DA-1241 which is a novel G-Protein-Coupled Receptor 119 (GPR119) and DA-1726 which is a novel oxyntomodulin (OXM) analog. The company also has four legacy therapeutics programs designed to impact a range of indications in viral, neurodegenerative, and cardiometabolic diseases: ANA001, NB-01, NB-02, and Gemcabene.
See More
Previous Close:
$0.85
Open:
$0.8245
24h Volume:
122.40K
Relative Volume:
0.27
Market Cap:
$7.09M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
+11.31%
1M Performance:
-48.07%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
Value
$0.8007
$0.85
1-Week Range:
Value
$0.67
$0.86
52-Week Range:
Value
$0.647
$2.75

Metavia Inc Stock (MTVA) Company Profile

Name
Name
Metavia Inc
Name
Phone
(857) 702-9600
Name
Address
545 CONCORD AVENUE, CAMBRIDGE
Name
Employee
8
Name
Twitter
Name
Next Earnings Date
Name
Latest SEC Filings
Name
MTVA's Discussions on Twitter

Compare MTVA with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
MTVA
Metavia Inc
0.8226 7.09M 0 0 0 0.00
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
493.84 122.76B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
602.64 61.38B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
614.76 36.37B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
251.56 30.12B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
244.90 24.70B 3.81B -644.79M -669.77M -6.24

Metavia Inc Stock (MTVA) Upgrades & Downgrades

Date Action Analyst Rating Change
Dec-30-24 Initiated H.C. Wainwright Buy

Metavia Inc Stock (MTVA) Latest News

pulisher
Apr 24, 2025

MetaVia’s Promising Clinical Trial Results and Future Prospects Drive Buy Rating - TipRanks

Apr 24, 2025
pulisher
Apr 23, 2025

MetaVia’s DA-1241 shows promise in Phase 2a MASH trial By Investing.com - Investing.com South Africa

Apr 23, 2025
pulisher
Apr 23, 2025

Copper Miner Rallies as Takeover Buzz Sparks Investor Optimism - The Globe and Mail

Apr 23, 2025
pulisher
Apr 23, 2025

MetaVia’s DA-1241 shows promise in Phase 2a MASH trial - Investing.com

Apr 23, 2025
pulisher
Apr 23, 2025

MetaVia Announces Late-Breaking Poster Presentation on DA-1241 at the EASL Congress 2025 - PR Newswire

Apr 23, 2025
pulisher
Apr 22, 2025

MetaVia’s ‘Safe’ Obesity Drug Resonates With Analysts, But Not Investors - insights.citeline.com

Apr 22, 2025
pulisher
Apr 22, 2025

MetaVia reports promising obesity drug trial results By Investing.com - Investing.com South Africa

Apr 22, 2025
pulisher
Apr 22, 2025

How will MetaVia Inc’s (MTVA) earnings compare to estimates this quarter? - uspostnews.com

Apr 22, 2025
pulisher
Apr 22, 2025

RIVN’s Q2 earnings predictions: What the experts say - uspostnews.com

Apr 22, 2025
pulisher
Apr 22, 2025

Can Newell Brands Inc (NWL) meet market expectations this quarter? - uspostnews.com

Apr 22, 2025
pulisher
Apr 22, 2025

MetaVia Reports Positive Phase 1 Trial Results - TipRanks

Apr 22, 2025
pulisher
Apr 22, 2025

MetaVia (MTVA) Reports Additional Positive Top-Line Results From the MAD Part 2 of Its Phase 1 Study of DA-1726 - StreetInsider

Apr 22, 2025
pulisher
Apr 22, 2025

MetaVia Reports Additional Positive Top-Line Results From The Mad Part 2 Of Its Phase 1 Study Of Da-1726, A Novel 31 Ratio Glp-1 And Glucagon Dual Receptor Agonist To Treat Obesity, Further Demonstrating Its Best-In-Class Potential - marketscreener.com

Apr 22, 2025
pulisher
Apr 22, 2025

MetaVia's New GLP-1 Drug Achieves 6.3% Weight Loss in Just 26 Days: Phase 1 Trial Reveals Promising Safety Profile - Stock Titan

Apr 22, 2025
pulisher
Apr 19, 2025

MetaVia’s (MTVA) Buy Rating Reiterated at HC Wainwright - Defense World

Apr 19, 2025
pulisher
Apr 18, 2025

MTVA stock touches 52-week low at $0.7 amid sharp annual decline - Investing.com Canada

Apr 18, 2025
pulisher
Apr 17, 2025

MTVA stock touches 52-week low at $0.7 amid sharp annual decline By Investing.com - Investing.com South Africa

Apr 17, 2025
pulisher
Apr 16, 2025

MTVA: Positive Phase 1 MAD Data for DA-1726; Excellent Tolerability Profile and Mean Day 26 Weight Loss of 4.3%… - Zacks Small Cap Research

Apr 16, 2025
pulisher
Apr 16, 2025

Korean Dental Association forms election planning team to enhance public oral healthCHOSUNBIZ - Chosunbiz

Apr 16, 2025
pulisher
Apr 16, 2025

MetaVia’s obesity drug cuts body weight by 6.3% in 26 days in phase 1 - koreabiomed.com

Apr 16, 2025
pulisher
Apr 16, 2025

MetaVia reports positive obesity drug trial results By Investing.com - Investing.com Canada

Apr 16, 2025
pulisher
Apr 15, 2025

12 Health Care Stocks Moving In Tuesday's After-Market Session - Benzinga

Apr 15, 2025
pulisher
Apr 15, 2025

U.S. stocks lower at close of trade; Dow Jones Industrial Average down 0.39% - Investing.com

Apr 15, 2025
pulisher
Apr 15, 2025

United States shares lower at close of trade; Dow Jones Industrial Average down 0.39% - Investing.com India

Apr 15, 2025
pulisher
Apr 15, 2025

12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga

Apr 15, 2025
pulisher
Apr 15, 2025

MetaVia Reports 'Positive' Results for Obesity Treatment in Part 2 of Phase 1 Trial - marketscreener.com

Apr 15, 2025
pulisher
Apr 15, 2025

Boehringer’s bispecific pact with Cue Biopharma; HepaRegeniX raises €21.5M - Endpoints News

Apr 15, 2025
pulisher
Apr 15, 2025

12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga

Apr 15, 2025
pulisher
Apr 15, 2025

Smart Shirt Might Predict Heart Problems - WFMZ.com

Apr 15, 2025
pulisher
Apr 15, 2025

MetaVia reports positive obesity drug trial results - Investing.com Australia

Apr 15, 2025
pulisher
Apr 15, 2025

MetaVia Announces Positive Phase 1 Trial Results - TipRanks

Apr 15, 2025
pulisher
Apr 15, 2025

Metavia Announces Positive Top-Line Data From The 4-Week Phase 1 Mad Trial Of Da-1726 - marketscreener.com

Apr 15, 2025
pulisher
Apr 15, 2025

MetaVia announces ‘positive’ results from Part 2 of Phase 1 trial of DA-1726 - TipRanks

Apr 15, 2025
pulisher
Apr 15, 2025

MetaVia (MTVA) Announces Positive Top-Line Data From the 4-Week Phase 1 MAD Trial of DA-1726 - StreetInsider

Apr 15, 2025
pulisher
Apr 15, 2025

MetaVia Announces Positive Top-Line Data From the 4-Week Phase 1 MAD Trial of DA-1726, a Novel 3:1 Ratio GLP-1 Glucagon Dual Receptor Agonist to Treat Obesity, Showing Compelling Weight Loss and Safety Effects With Potential Best-In-Class Glucos - PR Newswire

Apr 15, 2025
pulisher
Apr 14, 2025

Home-Delivered Medical Meals Could Prevent Millions Of Hospitalizations A Year - WFMZ.com

Apr 14, 2025
pulisher
Apr 14, 2025

SCHD ETF News, 4/14/2025 - The Globe and Mail

Apr 14, 2025
pulisher
Mar 31, 2025

MTVA: Phase 1 Part 2 Data for DA-1726 in Obesity Expected Soon… - Yahoo Finance

Mar 31, 2025
pulisher
Mar 24, 2025

MetaVia Inc. Reports Progress in Cardiometabolic Drug Development - MSN

Mar 24, 2025
pulisher
Mar 24, 2025

Alnylam Pharmaceuticals, Beacon Roofing, Liberty Energy - TradingView

Mar 24, 2025
pulisher
Mar 24, 2025

FY2029 Earnings Forecast for MetaVia Issued By HC Wainwright - Defense World

Mar 24, 2025
pulisher
Mar 23, 2025

HC Wainwright Reaffirms “Buy” Rating for MetaVia (NASDAQ:MTVA) - Defense World

Mar 23, 2025
pulisher
Mar 22, 2025

Positive Outlook on MetaVia’s Promising Pipeline and Strategic Growth Despite Market Challenges - TipRanks

Mar 22, 2025
pulisher
Mar 22, 2025

MetaVia Inc (MTVA) Reports Q4 EPS of -0.59, Revenue at $0 Millio - GuruFocus

Mar 22, 2025
pulisher
Mar 20, 2025

MetaVia Inc. (MTVA) reports earnings - Quartz

Mar 20, 2025
pulisher
Mar 20, 2025

Bank of England leaves benchmark interest rate unchanged at 4.50% with inflation still high - 69News WFMZ-TV

Mar 20, 2025
pulisher
Mar 20, 2025

Stock market today: Wall Street gives back some gains after the Fed extends interest rate pause - WFMZ.com

Mar 20, 2025
pulisher
Mar 20, 2025

MetaVia Reports Year End 2024 Financial Results and Provides Corporate Update - PR Newswire

Mar 20, 2025
pulisher
Mar 20, 2025

Tonsil Removal Helps Kids With Snoring/Sleep Apnea - 69News WFMZ-TV

Mar 20, 2025
pulisher
Mar 20, 2025

New Clot-Busting Drug Quicker And As Effective In Treating Stroke - 69News WFMZ-TV

Mar 20, 2025
pulisher
Mar 20, 2025

Ears Ringing? Diet Changes Might Reduce Risk Of Tinnitus - 69News WFMZ-TV

Mar 20, 2025

Metavia Inc Stock (MTVA) Financials Data

There is no financial data for Metavia Inc (MTVA). Check out other stocks for more information.

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$20.59
price up icon 0.24%
$69.69
price up icon 1.06%
$32.20
price up icon 0.53%
$23.46
price down icon 36.06%
$102.02
price down icon 15.36%
biotechnology ONC
$244.90
price down icon 4.40%
Cap:     |  Volume (24h):